CN104474571A - Starch compound polysaccharide hemostatic powder and preparation method thereof - Google Patents
Starch compound polysaccharide hemostatic powder and preparation method thereof Download PDFInfo
- Publication number
- CN104474571A CN104474571A CN201410659029.0A CN201410659029A CN104474571A CN 104474571 A CN104474571 A CN 104474571A CN 201410659029 A CN201410659029 A CN 201410659029A CN 104474571 A CN104474571 A CN 104474571A
- Authority
- CN
- China
- Prior art keywords
- starch
- solution
- preparation
- sodium
- powder
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Abstract
The invention relates to starch compound polysaccharide hemostatic powder and a preparation method thereof. The preparation method comprises the following steps: carrying out enzymatic denaturation on starch to obtain a porous starch solution, dissolving sodium hyaluronate in deionized water to obtain a sodium hyaluronate solution, mixing the two solutions according to a weight ratio of 50-95 parts of porous starch solution to 5-50 parts of sodium hyaluronate solution, stirring uniformly and drying, soaking the dried material in a calcium chloride solution with a certain concentration to carry out ion exchange, and grinding the material into powder after secondary drying. The material provided by the invention has efficient stypticity on wound surfaces, is biodegradable, has the functions of anti-adhesion and moisture retention, and is safe and non-toxic, simple in preparation process and low in cost.
Description
Technical field
The invention belongs to biological medicine Material Field, be specifically related to a kind of starch complex polysaccharide styptic powder and preparation method thereof.
Background technology
Medically, hemorrhagely refer to that blood accumulates in body cavity, interstice from heart or blood vessel or flows out external.Normal human all has hemostatic function, slowly a small amount of hemorrhage self function that can rely on is stopped blooding, but, the disguised oozing phenomenon broken for human body massive hemorrhage phenomenon, internal organs etc. in various sudden accident not only body can not stop blooding voluntarily, is also the difficult problem in operation, if patient's severe loss of blood, shock may be caused, even entail dangers to life and health, so, need to stop blooding fast and effectively in the process of operation.Generally, doctor needs to take some hemostatic techniques to stop blooding usually, along with the development of science and technology, hemostatic fashion also develops into gradually from mechanical hemostasis such as traditional ligation, stitching, coagulations and uses hemostatic material hemostasis, develops a kind of excellent performance, focus that the hemostatic material of quick-acting haemostatic powder becomes research.
At present, the hemostatic material used clinically mainly contains Fibrin Glue, collagen protein, gelfoam and cellulose hemostatic material, and these materials all come with some shortcomings: collagen, gelatin class, and its raw material sources are in animal, there is potential sensitization, and infiltration rate is slow; Cellulose family, human body lacks the enzyme making it degrade, and degradation time is long, may bring the side effect such as infection to patient.
Starch is plant polysaccharide, its good biocompatibility, nontoxic, non-stimulated, the anaphylaxis that not easily causes body.Starch hemostatic material representative is at present Arista styptic powder produced in USA, although its haemostatic effect is good, but still Shortcomings: first, adopt epichlorohydrin cross-linked, there is genotoxic potential; Two is that cohesiveness is not good; Three is expensive, limits its application.Hyaluronic acid hyaluronic acid, is Hyaluronic Acid again, is a kind of natural Moisture factor, can be suppressed to fibrocyte proliferation in the process of wound healing, have anti effect.
Summary of the invention
The invention provides a kind of starch complex polysaccharide styptic powder, for solving the problems of the prior art, this material has efficient anastalsis to wound surface, biodegradable, and there is effect, the safety non-toxic of anti and moisturizing, preparation technology is simple, with low cost, and provides the preparation method of this material.
A kind of starch complex polysaccharide of the present invention styptic powder, made containing calcium ion in material by ion exchange, when material contacts with wound surface, calcium ion is released, and the gel of material water suction simultaneously, has anti and moisture-keeping efficacy; Porous-starch in this starch-polysaccharides styptic powder has strong imbibition ability, can the moisture of absorbing blood fast when imposing on wound surface, and reach the object of hemostasis, meanwhile, the calcium ion be released has again certain thromboplastic effect, strengthens anastalsis.
Preparation method of the present invention, comprises the steps:
1) getting a certain amount of starch is dissolved in deionized water, be 1:(0.005 ~ 0.03 by the weight ratio with enzyme), take α-amylase or saccharifying enzyme, and be dissolved in phosphate buffer, starch solution is mixed with enzymatic solution, 50 ± 5 DEG C, under the condition of pH3 ~ 6, react at least 24h and obtain the starch solution that mass volume ratio is 25 ~ 30%, for subsequent use;
2) getting hyaluronate sodium is dissolved in deionized water, is mixed with the sodium hyaluronate solution that mass volume ratio is 0.5 ~ 1.0%, for subsequent use;
4) getting a certain amount of calcium chloride is dissolved in deionized water, is mixed with the calcium chloride solution that concentration is 1 ~ 15%, for subsequent use;
3) starch solution of above-mentioned preparation and sodium hyaluronate solution are calculated by weight, starch 50 ~ 95 parts, hyaluronate sodium 5 ~ 50 parts, blended, stir, vacuum lyophilization;
5) described starch/hyaluronate sodium dry composite thing is soaked in described calcium chloride solution 0.5 ~ 4h to take out, fully rinse with distilled water, crushed into powder after lyophilization.
The present invention by porous-starch and hyaluronate sodium blended according to certain ratio, by ion exchange, obtained a kind of starch complex polysaccharide styptic powder.
Starch/hyaluronate sodium compound hemostatic powder prepared by the present invention's said method has good biocompatibility and degradability, safety non-toxic, can quick-acting haemostatic powder when contacting with wound surface, these starch complex polysaccharide styptic powder raw material sources are extensive, preparation technology simple, have feature cheap, easy and simple to handle.
Detailed description of the invention
In order to understand technical scheme of the present invention better, be described in further detail by following specific embodiment
Embodiment 1:
Take the starch of 80g, the α-amylase of 0.4g or saccharifying enzyme, blended after being dissolved in respectively in buffer, 50 ± 5 DEG C, pH3 ~ 6, reaction 24h obtain the starch solution that mass percentage concentration is 25%, for subsequent use; Getting 20g hyaluronate sodium is dissolved in deionized water, is made into the sodium hyaluronate solution that mass percentage concentration is 1%, for subsequent use; By the starch solution for preparing and sodium hyaluronate solution mixing and stirring, then lyophilization; Take a certain amount of calcium chloride, be dissolved in deionized water, preparation mass percentage concentration is the calcium chloride solution of 5%; Drying sample material is dipped in 2h in the calcium chloride solution of 5%, take out, fully rinse with distilled water, crushed into powder after lyophilization, is spread on bleeding part after sterilizing, directly uses hemostasis.
Embodiment 2:
Take the starch of 90g, the α-amylase of 0.9g or saccharifying enzyme, blended after being dissolved in respectively in buffer, 50 ± 5 DEG C, pH3 ~ 6, reaction 24h obtain the starch solution that mass percentage concentration is 25%, for subsequent use; Getting 10g hyaluronate sodium is dissolved in deionized water, is made into the sodium hyaluronate solution that mass percentage concentration is 1%, for subsequent use; By the starch solution for preparing and sodium hyaluronate solution mixing and stirring, then lyophilization; Take a certain amount of calcium chloride, be dissolved in deionized water, preparation mass percentage concentration is the calcium chloride solution of 5%; Drying sample material is dipped in 2h in the calcium chloride solution of 5%, take out, fully rinse with distilled water, crushed into powder after lyophilization, is spread on bleeding part after sterilizing, directly uses hemostasis.
Embodiment 3:
Take the starch of 90g, the α-amylase of 0.9g or saccharifying enzyme, blended after being dissolved in respectively in buffer, 50 ± 5 DEG C, pH3 ~ 6, reaction 24h obtain the starch solution that mass percentage concentration is 30%, for subsequent use; Getting 10g hyaluronate sodium is dissolved in deionized water, is made into the sodium hyaluronate solution that mass percentage concentration is 0.5%, for subsequent use; By the starch solution for preparing and sodium hyaluronate solution mixing and stirring, then lyophilization; Take a certain amount of calcium chloride, be dissolved in deionized water, preparation mass percentage concentration is the calcium chloride solution of 5%; Drying sample material is dipped in 2h in the calcium chloride solution of 5%, take out, fully rinse with distilled water, crushed into powder after lyophilization, is spread on bleeding part after sterilizing, directly uses hemostasis.
Embodiment 4:
Take the starch of 90g, the α-amylase of 0.9g or saccharifying enzyme, blended after being dissolved in respectively in buffer, 50 ± 5 DEG C, pH3 ~ 6, reaction 24h obtain the starch solution that mass percentage concentration is 25%, for subsequent use; Getting 10g hyaluronate sodium is dissolved in deionized water, is made into the sodium hyaluronate solution that mass percentage concentration is 1%, for subsequent use; By the starch solution for preparing and sodium hyaluronate solution mixing and stirring, then lyophilization; Take a certain amount of calcium chloride, be dissolved in deionized water, preparation mass percentage concentration is the calcium chloride solution of 10%; Drying sample material is dipped in 1h in the calcium chloride solution of 10%, take out, fully rinse with distilled water, crushed into powder after lyophilization, is spread on bleeding part after sterilizing, directly uses hemostasis.
Embodiment 5:
Take the starch of 95g, the α-amylase of 0.95g or saccharifying enzyme, blended after being dissolved in respectively in buffer, 50 ± 5 DEG C, pH3 ~ 6, reaction 24h obtain the starch solution that mass percentage concentration is 25%, for subsequent use; Getting 5g hyaluronate sodium is dissolved in deionized water, is made into the sodium hyaluronate solution that mass percentage concentration is 1%, for subsequent use; By the starch solution for preparing and sodium hyaluronate solution mixing and stirring, then lyophilization; Take a certain amount of calcium chloride, be dissolved in deionized water, preparation mass percentage concentration is the calcium chloride solution of 10%; Drying sample material is dipped in 1h in the calcium chloride solution of 10%, take out, fully rinse with distilled water, crushed into powder after lyophilization, is spread on bleeding part after sterilizing, directly uses hemostasis.
Claims (5)
1. a starch complex polysaccharide styptic powder, is characterized in that, described complex polysaccharide styptic powder main component is starch, hyaluronate sodium, wherein starch 50 ~ 95 parts, hyaluronate sodium 5 ~ 50 parts.
2. starch complex polysaccharide styptic powder as claimed in claim 1, it is characterized in that, described starch is the porous-starch after enzymolysis, and enzyme used is the one in α-amylase, saccharifying enzyme.
3. the preparation method of starch complex polysaccharide styptic powder as claimed in claim 1 or 2, it is characterized in that, starch solution and sodium hyaluronate solution are stirred under certain conditions, is dipped in after lyophilization in ionic calcium soln and carries out ion exchange, after redrying, obtain styptic powder.
4. the preparation method of starch complex polysaccharide styptic powder as claimed in claim 3, is characterized in that,
1) get a certain amount of starch to be dissolved in deionized water and to obtain starch solution, be 1:(0.005 ~ 0.03 by the weight ratio of starch and enzyme), take α-amylase or saccharifying enzyme, and be dissolved in phosphate buffer and obtain enzymatic solution, starch solution is mixed with enzymatic solution, 50 ± 5 DEG C, under the condition of pH3 ~ 6, react at least 24h and obtain the starch solution that mass volume ratio is 25 ~ 30%;
2) getting hyaluronate sodium is dissolved in deionized water, is mixed with the sodium hyaluronate solution that mass volume ratio is 0.5 ~ 1.0%;
3) starch solution of above-mentioned preparation and sodium hyaluronate solution are calculated by weight, starch 50 ~ 95 parts, hyaluronate sodium 5 ~ 50 parts, blended, stir, vacuum lyophilization;
4) getting a certain amount of calcium chloride is dissolved in deionized water, is mixed with the calcium chloride solution that concentration is 1 ~ 15%;
5) described starch/hyaluronate sodium dry composite thing is soaked in described calcium chloride solution 0.5 ~ 4h to take out, fully rinse with distilled water, crushed into powder after lyophilization.
5. the application of starch complex polysaccharide styptic powder as claimed in claim 1, is characterized in that, be applied to various traumatic hemorrhage, surgical operation wound surface is hemorrhage, oozing of blood, the hemostasis of chamber mirror, the hemorrhage oozing of blood of endoscope etc.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201410659029.0A CN104474571A (en) | 2014-11-19 | 2014-11-19 | Starch compound polysaccharide hemostatic powder and preparation method thereof |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201410659029.0A CN104474571A (en) | 2014-11-19 | 2014-11-19 | Starch compound polysaccharide hemostatic powder and preparation method thereof |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CN104474571A true CN104474571A (en) | 2015-04-01 |
Family
ID=52749266
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN201410659029.0A Pending CN104474571A (en) | 2014-11-19 | 2014-11-19 | Starch compound polysaccharide hemostatic powder and preparation method thereof |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN104474571A (en) |
Cited By (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN109125794A (en) * | 2018-09-07 | 2019-01-04 | 广州迈普再生医学科技股份有限公司 | A kind of degradable high water-absorbing styptic powder and its preparation method and application |
| CN109498832A (en) * | 2017-09-15 | 2019-03-22 | 中国药科大学 | A kind of cross-linked porous hemostatic microsphere and preparation method thereof |
| CN112675356A (en) * | 2020-12-23 | 2021-04-20 | 湖南工业大学 | Long-term-preservation hemostatic composition, preparation method thereof and preparation method of long-term-preservation antibacterial hemostatic mixture |
| CN116099059A (en) * | 2023-04-13 | 2023-05-12 | 中日友好医院(中日友好临床医学研究所) | Injectable antibacterial fistula blocking hydrogel and preparation method thereof |
| CN116159192A (en) * | 2023-04-20 | 2023-05-26 | 中日友好医院(中日友好临床医学研究所) | Injectable hemostatic anti-adhesion hydrogel and preparation method thereof |
Citations (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20090020797A1 (en) * | 2006-03-30 | 2009-01-22 | Fujitsu Limited | Semiconductor device and method of manufacturing the same |
| CN103041448A (en) * | 2013-01-17 | 2013-04-17 | 苏州博创同康生物工程有限公司 | Compound polysaccharide hemostatic material and preparation method and application thereof |
| CN103055343A (en) * | 2011-10-19 | 2013-04-24 | 袁暾 | Potato starch-hyaluronic acid composite hemostatic powder and preparation method thereof |
| CN103550815A (en) * | 2013-11-07 | 2014-02-05 | 梁新丽 | Preparation method of microporous polysaccharide microspheres |
| CN104546893A (en) * | 2014-01-07 | 2015-04-29 | 北京大清生物技术有限公司 | Biodegradable and absorbable hemostasis composition |
-
2014
- 2014-11-19 CN CN201410659029.0A patent/CN104474571A/en active Pending
Patent Citations (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20090020797A1 (en) * | 2006-03-30 | 2009-01-22 | Fujitsu Limited | Semiconductor device and method of manufacturing the same |
| CN103055343A (en) * | 2011-10-19 | 2013-04-24 | 袁暾 | Potato starch-hyaluronic acid composite hemostatic powder and preparation method thereof |
| CN103041448A (en) * | 2013-01-17 | 2013-04-17 | 苏州博创同康生物工程有限公司 | Compound polysaccharide hemostatic material and preparation method and application thereof |
| CN103550815A (en) * | 2013-11-07 | 2014-02-05 | 梁新丽 | Preparation method of microporous polysaccharide microspheres |
| CN104546893A (en) * | 2014-01-07 | 2015-04-29 | 北京大清生物技术有限公司 | Biodegradable and absorbable hemostasis composition |
Cited By (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN109498832A (en) * | 2017-09-15 | 2019-03-22 | 中国药科大学 | A kind of cross-linked porous hemostatic microsphere and preparation method thereof |
| CN109125794A (en) * | 2018-09-07 | 2019-01-04 | 广州迈普再生医学科技股份有限公司 | A kind of degradable high water-absorbing styptic powder and its preparation method and application |
| CN109125794B (en) * | 2018-09-07 | 2021-08-31 | 广州迈普再生医学科技股份有限公司 | Degradable high-water-absorptivity hemostatic powder and preparation method and application thereof |
| CN112675356A (en) * | 2020-12-23 | 2021-04-20 | 湖南工业大学 | Long-term-preservation hemostatic composition, preparation method thereof and preparation method of long-term-preservation antibacterial hemostatic mixture |
| CN116099059A (en) * | 2023-04-13 | 2023-05-12 | 中日友好医院(中日友好临床医学研究所) | Injectable antibacterial fistula blocking hydrogel and preparation method thereof |
| CN116159192A (en) * | 2023-04-20 | 2023-05-26 | 中日友好医院(中日友好临床医学研究所) | Injectable hemostatic anti-adhesion hydrogel and preparation method thereof |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP6868314B2 (en) | Wound dressing containing hyaluronic acid-calcium and polylysine and its manufacturing method | |
| JP6050320B2 (en) | Hemostatic composition | |
| EP2233157A1 (en) | A biocompatible denatured starch sponge material | |
| CN106620824B (en) | A kind of preparation method of high-efficiency antimicrobial compound hemostatic sponge | |
| CN107243086A (en) | A kind of absorbable compound hemostatic powder and preparation method thereof | |
| CN104474571A (en) | Starch compound polysaccharide hemostatic powder and preparation method thereof | |
| WO2009091549A1 (en) | Modified starch material of biocompatible hemostasis | |
| CN105597144A (en) | Absorbable collagen styptic powder and preparing method thereof | |
| CN108853570B (en) | Hemostatic sponge and preparation method thereof | |
| CN105797203A (en) | Alginate fiber based collagen sponge dressing and preparation method thereof | |
| CN102526794A (en) | Calcium-complex starch-based microporous haemostatic material, and preparation method and application thereof | |
| CN104606723B (en) | Absorbability starch hemostatic powder and preparation method thereof, application | |
| JP6807922B2 (en) | Biocompatible carboxymethyl cellulose matrix (BCM) for hemostasis, tissue barrier, wound healing, and cosmetology | |
| CN109172857A (en) | A kind of outer wound compound hemostatic material and preparation method thereof | |
| CN105727347A (en) | Composite hemostatic sponge and preparation method thereof | |
| CN113908330B (en) | Preparation method of composite gel with photothermal antibacterial hemostatic characteristics, product and application thereof | |
| CN106975098A (en) | A kind of complex polysaccharide hemostatic composition and preparation method and application | |
| CN103333261B (en) | A kind of hemostatic starch and preparation method thereof | |
| CN104069535B (en) | A kind of Preparation method and use of biological activity composite membrane bleeding-stopping dressing | |
| CN101450223A (en) | Hemostasia material based on chitosan, collagen and sodium cellulose glycolate and preparation method and use thereof | |
| CN106693038A (en) | Preparation method of antibacterial hemostatic medical sponge | |
| CN109498833A (en) | A kind of Medical absorbable polysaccharide composite material and application thereof | |
| CN102008740B (en) | Absorbable growth factor composite dressing | |
| CN109125795B (en) | Polysaccharide hemostatic composition and preparation method and application thereof | |
| CN106540310A (en) | A kind of absorbability rapid hemostatic material and preparation method thereof |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| C06 | Publication | ||
| PB01 | Publication | ||
| C10 | Entry into substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| RJ01 | Rejection of invention patent application after publication |
Application publication date: 20150401 |
|
| RJ01 | Rejection of invention patent application after publication |